Pediatrix Medical price target lowered to $21 from $24 at Truist

Truist lowered the firm’s price target on Pediatrix Medical (MD) to $21 from $24 and keeps a Hold rating on the shares. The firm maintained its Hold view following Q4 results, with adjusted EBITDA shy of its expectations and consensus and initial FY26 guidance ahead of consensus and in-line with the firm’s view at the midpoint. Q4 revenue was slightly below the firm’s estimate, and volumes were negative, the analyst tells investors in a research note.